Record number:
89
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
Most recent risk assessment for medulloblastoma (Council of Europe, 2022):
Childhood medulloblastomas are the CNS primitive tumours that metastasize most frequently outside the CNS. The risk may be increased if prior ventriculo-peritoneal or ventricular-atrial shunts, tumour resection or cranial chemo-/radiotherapy have been performed. Organs from potential donors with medulloblastomas (WHO grade IV) are considered intermediate to high risk for tumour transmission, depending on different international recommendations, which will be adjusted with increasing evidence. They should be used exclusively for transplants where the recipient’s risk of dying while on the waiting list is greater than the risk of tumour transmission.
Time to detection:
4 months
Alerting signals, symptoms, evidence of occurrence:
First presented in kidney-pancreas recipient (pancreas removed on day 3 due to thrombosis). At 4 months, anuria and renal enlargement. Kidney, kidney-pancreas, and heart recipients developed disseminated tumors resulting in the death of two (heart, kidney-pancreas recipient).
Demonstration of imputability or root cause:
Condition known in the donor whose cause of death was medulloblastoma after placement of a ventriculo-peritoneal shunt. More than one recipient affected.
Imputability grade:
3 Definite/Certain/Proven
Groups audience:
Keywords:
Suggest new keywords:
Case report
Deceased donor
DBD/donation after brain death
Central nervous system
Pancreas transplant
Heart transplant
Kidney transplant
Chemotherapy
Suggest references:
aaa